Citation Impact
Citing Papers
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
2019
Cytotoxic T Lymphocyte Antigen-4 Blockade Enhances Antitumor Immunity by Stimulating Melanoma-Specific T-cell Motility
2014 StandoutNobel
Infrared molecular fingerprinting of blood-based liquid biopsies for the detection of cancer
2021 StandoutNobel
Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: A retrospective, population-based study
2010
Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis
2014 StandoutNobel
Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again
2018 StandoutNobel
Individual differences in endogenous pain modulation as a risk factor for chronic pain
2005
Cancer–stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis
2012 StandoutNobel
Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer
2016
Hallmarks of Cancer: The Next Generation
2011 Standout
Triple-negative breast cancer molecular subtyping and treatment progress
2020 Standout
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
2020 Standout
NeuPSIG guidelines on neuropathic pain assessment
2010 Standout
Geographic and racial aspects of herpes zoster
2003
Cancer to bone: a fatal attraction
2011 Standout
The role of sympathetic nerve blocks in herpes zoster and postherpetic neuralgia
2000
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
2012 Standout
Oral brivudin in comparison with acyclovir for improved therapy of herpes zoster in immunocompetent patients: results of a randomized, double-blind, multicentered study
2003
Treatment of postherpetic neuralgia: a review of therapeutic options
2004
Drug development and clinical trials—the path to an approved cancer drug
2012
Liquid biopsy enters the clinic — implementation issues and future challenges
2021
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Cancer immunotherapy via dendritic cells
2012 Standout
A systematic review and meta-analysis of risk factors for postherpetic neuralgia
2015
Hepatocellular carcinoma
2021 Standout
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
2021 Standout
Imaging angiogenesis of genitourinary tumors
2010
Predicting postherpetic neuralgia in elderly primary care patients with herpes zoster: Prospective prognostic study
2007
Current and future perspectives of liquid biopsies in genomics-driven oncology
2018 Standout
The Erector Spinae Plane Block
2016 Standout
Delivery technologies for cancer immunotherapy
2019 Standout
Pharmacologic management of neuropathic pain: Evidence-based recommendations
2007 Standout
The hypoxic tumor microenvironment: A driving force for breast cancer progression
2015 StandoutNobel
Sex, Gender, and Pain: A Review of Recent Clinical and Experimental Findings
2009 Standout
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
2011 StandoutNobel
Raise standards for preclinical cancer research
2012 StandoutNature
Epidemiology and Impact on Quality of Life of Postherpetic Neuralgia and Painful Diabetic Neuropathy
2002
Hypoxia and TGF-β Drive Breast Cancer Bone Metastases through Parallel Signaling Pathways in Tumor Cells and the Bone Microenvironment
2009
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
2011
Treatment of Postherpetic Neuralgia
2000
Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer
2015 Nature
Persistent postsurgical pain: risk factors and prevention
2006 Standout
Zibotentan for the treatment of castrate-resistant prostate cancer
2010
Cancer immunotherapy comes of age
2011 StandoutNature
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 Standout
Repertoire Enhancement with Adoptively Transferred Female Lymphocytes Controls the Growth of Pre-Implanted Murine Prostate Cancer
2012 StandoutNobel
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
2015 Standout
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology
2018
Herpes Zoster
2013 Standout
Herpes Zoster
2002 Standout
A Population-Based Study of the Incidence and Complication Rates of Herpes Zoster Before Zoster Vaccine Introduction
2007 Standout
Hepatocellular carcinoma
2022 Standout
Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review
2017
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
2017 Standout
New Therapeutic Approach to Suppress Castration-Resistant Prostate Cancer Using ASC-J9 via Targeting Androgen Receptor in Selective Prostate Cells
2012
Systematic review of incidence and complications of herpes zoster: towards a global perspective
2014 Standout
Hypoxia-inducible factor 1 mediates TAZ expression and nuclear localization to induce the breast cancer stem cell phenotype
2014 StandoutNobel
Risk factors for postherpetic neuralgia in patients with herpes zoster
2004
Current concepts in the diagnosis and management of cytokine release syndrome
2014 Standout
Enzalutamide for the Treatment of Prostate Cancer: Results and Implications of the AFFIRM Trial
2014
The lifetime occurrence of Herpes zoster and prevalence of post‐herpetic neuralgia: A retrospective survey in an elderly population
1999
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Predictors of Postherpetic Neuralgia Among Patients With Herpes Zoster: A Prospective Study
2010
Role of Hypoxia-Inducible Factors in Breast Cancer Metastasis
2013 StandoutNobel
Neuropathic Pain: From Mechanisms to Treatment
2020 Standout
Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
2018
Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines
2018 Standout
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
2021 Standout
Natural product and natural product derived drugs in clinical trials
2014 Standout
Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP).
2008 Standout
Post-herpetic neuralgia
2016
Bone Metastases: Molecular Mechanisms and Novel Therapeutic Interventions
2010
2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host
2013 Standout
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
Up-Regulation of PD-L1, IDO, and T regs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T Cells
2013 Standout
American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update
2014 Standout
Cancer treatment and survivorship statistics, 2014
2014 Standout
Works of De Phung being referenced
Adjusting Overall Survival Estimates after Treatment Switching: a Case Study in Metastatic Castration-Resistant Prostate Cancer
2016
A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer
2009
Postherpetic Neuralgia: Impact of Famciclovir, Age, Rash Severity, and Acute Pain in Herpes Zoster Patients
1998
Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Trial
2008
Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study
2016
Combined Androgen Blockade in Advanced Prostate Cancer: Looking Back to Move Forward
2007
Circulating tumor cell (CTC) enumeration in men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide post-chemotherapy (phase 3 AFFIRM study).
2015
Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial
2016
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
2018
Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration‐resistant prostate cancer and bone metastases who were pain‐free or mildly symptomatic for pain: a double‐blind, placebo‐controlled, randomized Phase II trial
2010
Enzalutamide (ENZA) in combination with abiraterone acetate (AA) in bone metastatic castration resistant prostate cancer (mCRPC).
2014
Efficacy and safety of enzalutamide (ENZA) monotherapy in hormone-naive prostate cancer (HNPC).
2013
Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo
2017